Abbott Exits Boehringer Ingelheim Distribution Deal Early
This article was originally published in The Pink Sheet Daily
Executive Summary
Termination of the agreement to distribute Mobic, Flomax and Micardis in the U.S. is expected to boost Abbott’s gross margins, the company reports.